)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Syncona
Syncona (SYNC) investor relations material
Syncona Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary6 Aug, 2026
Executive summary
Achieved meaningful progress across the portfolio, including first patient dosed in Spur's Phase III pivotal trial and positive clinical updates from Resolution and Spur.
Four key value inflection points expected by end of CY2026, with additional milestones through CY2028, positioning the portfolio for significant upside.
Leadership changes and appointments across several portfolio companies to support strategic growth and operational execution.
Financial highlights
Net assets at £1,038.1 million, 170.6p per share as of 30 June 2026, with a NAV per share return of 0.0% for the quarter.
Life Science Portfolio valued at £866.7 million, up from £839.4 million, a 0.5% return in the quarter.
Capital pool of £171.4 million, with £24.9 million deployed during the quarter, all into late-stage and clinical-stage companies.
Outlook and guidance
Portfolio is well positioned to deliver significant upside, with potential for £250 million in proceeds to shareholders as key milestones are achieved.
Four capital access milestones and four key value inflection points targeted by end of CY2026, with further milestones through CY2028.
Mosaic Therapeutics adjusted its clinical study initiation to CY2027, reflecting a new strategic focus.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Syncona
- NAV stable, 1.7% portfolio return, and GBP 250 million in realizations targeted.SYNC
H2 2026 - NAV per share rose 3.6% as late-stage clinical assets and Beacon's uplift drove portfolio gains.SYNCQ3 2026 TU
- NAV fell (1.7)% to £1,020.9m; five value inflection points and £250m return targeted.SYNCH1 2026
- NAV per share rose 0.5% as clinical and strategic milestones drove portfolio growth.SYNCQ1 2026 TU
- NAV per share down 9.5% to 170.9p, portfolio 78.5% clinical, strategic plan for cash returns.SYNCH2 2025
- NAV fell 5.2% as late-stage portfolio advanced, with FDA approval and capital inflows supporting growth.SYNCH1 2025
- Portfolio value declined as quoted holdings fell, but clinical-stage assets and capital inflows grew.SYNCQ1 2025 TU
- NAV up 1.2% to GBP 1.2bn, portfolio 71% clinical stage, and GBP 60m buyback supports growth.SYNCH2 2024
- Q3 saw stable NAV, key clinical milestones, and disciplined capital deployment despite market headwinds.SYNCQ3 2025 TU
Next Syncona earnings date
Q2 202712 Nov, 2026
Syncona
Next Syncona earnings date
Q2 202712 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage